Criteria Developed for PET-Based Examinations of Malignant Brain Tumors
An international team of researchers (RANO Working Group), led by scientists from Ludwig-Maximilians-Universität München (LMU) and the Medical University of Vienna, has now drawn up the ﬁrst ever international criteria for the standardized imaging of gliomas using amino acid PET. It has published its results in the journal The Lancet Oncology.
Diffuse gliomas are malignant brain tumors that cannot be optimally examined by means of conventional MRI imaging. So-called amino acid PET scans are better able to image the activity and spread of gliomas. Under the joint leadership of nuclear physician Nathalie Albert from LMU and oncologist Professor Matthias Preusser from the Medical University of Vienna, the RANO group has developed new criteria for assessing the success of therapies for diffuse gliomas. These malignant brain tumors develop out of glial cells in the brain. Tumors of this kind are generally aggressive and difﬁcult to treat. The RANO group has developed criteria that permit evaluation of the success of treatment using positron emission tomography (PET). Called PET RANO 1.0, these PET-based criteria open up new possibilities for the standardized assessment of diffuse gliomas.
Amino acid PET is used in the diagnosis of diffuse gliomas, with tracers that work on a protein basis (amino acids) and accumulate in brain tumors. Nathalie Albert explains, “PET imaging with radioactively labeled amino acids has proven extremely valuable in neuro-oncology and permits reliable representation of the activity and extension of gliomas. Although amino acid PET has been used for years, it had not been evaluated in a structured manner before now. In contrast to MRI-based diagnostics, there have been no criteria for interpreting these PET images.” According to the researchers, the new criteria allow PET to be used in clinical studies and everyday clinical practice and create a foundation for future research and the comparison of treatments for improved therapies.
The Response Assessment in Neuro-Oncology (RANO) Working Group is an international, multidisciplinary consortium founded to develop standardized new response criteria for clinical studies relating to brain tumors. Comprising experts from various ﬁelds, the group has been developing criteria to serve as standard references for assessing various clinically relevant aspects for more than a decade.
Call for Papers
ARO is seeking original case reports, research articles, and review articles on innovative topics offering practical applications in radiation oncology. Manuscripts undergo a double-blinded external peer review process, and there is no submission fee.
- First Clinical Results Published for 177Lu-rhPSMA-10.1 in mCRPC Trial
- Opaganib Shown to Protect Against Radiation-Induced Lung Inflammation
- Fusion Licenses Actinium-Based PSMA Targeted Radiotherapy From Heidelberg University and Euratom
- Future of Theranostics in Neurooncology Looks Promising With Recent Advancements
- First Cellular Therapy for Unresectable or Metastatic Melanoma Receives FDA Approval